MCID: HYP025
MIFTS: 48

Hyperphosphatemia

Categories: Metabolic diseases

Aliases & Classifications for Hyperphosphatemia

MalaCards integrated aliases for Hyperphosphatemia:

Name: Hyperphosphatemia 12 29 55 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0050459
MeSH 44 D054559
NCIt 50 C113750
SNOMED-CT 68 20165001
UMLS 73 C0085681

Summaries for Hyperphosphatemia

MalaCards based summary : Hyperphosphatemia is related to tumoral calcinosis, hyperphosphatemic, familial, 1 and pseudohypoparathyroidism, type ib. An important gene associated with Hyperphosphatemia is FGF23 (Fibroblast Growth Factor 23), and among its related pathways/superpathways are Signaling by FGFR2 and Endochondral Ossification. The drugs Calcium Carbonate and Alendronate have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and liver, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 76 Hyperphosphatemia is an electrolyte disturbance in which there is an abnormally elevated level of... more...

Related Diseases for Hyperphosphatemia

Diseases related to Hyperphosphatemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 107)
# Related Disease Score Top Affiliating Genes
1 tumoral calcinosis, hyperphosphatemic, familial, 1 34.0 FGF23 GALNT3 KL
2 pseudohypoparathyroidism, type ib 32.1 GNAS PTH STX16
3 hypoparathyroidism, familial isolated 31.0 CASR GCM2 PTH
4 hyperostosis 30.9 FGF23 GALNT3 KL
5 hypocalcemia, autosomal dominant 1 30.2 CASR GCM2 GNAS VDR
6 familial tumoral calcinosis 30.0 FGF23 GALNT3 KL PHEX
7 hypophosphatemia 29.6 FGF23 PHEX PTH SLC34A1
8 calcinosis 29.5 FGF23 GALNT3 KL MGP PHEX
9 chronic kidney failure 29.4 CASR FGF23 PTH VDR
10 hypophosphatasia 29.4 PHEX RUNX2
11 uremia 29.1 CASR PTH VDR
12 hypoparathyroidism 28.9 CASR FGF23 GCM2 PTH
13 secondary hyperparathyroidism of renal origin 28.8 CASR FGF23 PTH VDR
14 kidney disease 28.5 CASR FGF23 MGP PTH VDR
15 calciphylaxis 28.3 CASR FGF23 PTH VDR
16 hyperparathyroidism 27.8 CASR FGF23 GCM2 PHEX PTH VDR
17 bone disease 27.4 CASR FGF23 PTH RUNX2 VDR
18 osteoporosis 24.9 CASR FGF23 KL MGP PTH RUNX2
19 hyperphosphatemia, polyuria, and seizures 12.0
20 tumoral calcinosis, hyperphosphatemic, familial, 2 11.0
21 tumoral calcinosis, hyperphosphatemic, familial, 3 11.0
22 pseudohypoparathyroidism, type ia 10.8
23 pseudohypoparathyroidism, type ii 10.8
24 hypoparathyroidism-retardation-dysmorphism syndrome 10.8
25 pseudohypoparathyroidism, type ic 10.8
26 tracheal calcification 10.7 FGF23 KL
27 impaired renal function disease 10.6 FGF23 PTH
28 chief cell adenoma 10.5 GCM2 PTH
29 opsismodysplasia 10.5 FGF23 PHEX
30 enthesopathy 10.5 FGF23 PHEX
31 autosomal recessive hypophosphatemic rickets 10.5 FGF23 PHEX
32 albright's hereditary osteodystrophy 10.5 GNAS STX16
33 metaphyseal chondrodysplasia, jansen type 10.4 FGF23 PTH
34 pseudopseudohypoparathyroidism 10.4 GNAS PTH STX16
35 urinary system disease 10.3 FGF23 KL PTH
36 metal metabolism disorder 10.3 GNAS PTH STX16
37 hypophosphatemic rickets, autosomal dominant 10.3 FGF23 GALNT3 PHEX
38 pseudohypoparathyroidism 10.3 GNAS PTH STX16
39 oncogenic osteomalacia 10.3 FGF23 PHEX PTH
40 arterial calcification of infancy 10.3 FGF23 GALNT3 PHEX
41 peritonitis 10.3
42 pulmonary alveolar microlithiasis 10.2 FGF23 PTH SLC34A1
43 leukemia 10.2
44 osseous heteroplasia, progressive 10.1 GNAS RUNX2
45 lymphoblastic leukemia 10.1
46 leukemia, acute lymphoblastic 10.1
47 spondylosis 10.0 KL PTH VDR
48 glucocorticoid-induced osteoporosis 10.0 PTH RUNX2
49 myeloma, multiple 10.0
50 lactic acidosis 10.0

Graphical network of the top 20 diseases related to Hyperphosphatemia:



Diseases related to Hyperphosphatemia

Symptoms & Phenotypes for Hyperphosphatemia

MGI Mouse Phenotypes related to Hyperphosphatemia:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.26 FGF23 GALNT3 GNAS KL MGP PHEX
2 homeostasis/metabolism MP:0005376 10.25 CASR FGF23 GALNT3 GCM2 GNAS KL
3 cardiovascular system MP:0005385 10.2 FGF23 GALNT3 GNAS KL MGP PTH
4 cellular MP:0005384 10.19 GALNT3 GCM2 GNAS KL PHEX PTH
5 endocrine/exocrine gland MP:0005379 10.15 CASR FGF23 GALNT3 GCM2 GNAS KL
6 craniofacial MP:0005382 10.13 GALNT3 GCM2 GNAS KL PHEX PTH
7 hematopoietic system MP:0005397 10.11 CASR FGF23 GALNT3 GNAS KL PHEX
8 immune system MP:0005387 10.06 CASR FGF23 GALNT3 GNAS KL PHEX
9 digestive/alimentary MP:0005381 10.05 CASR FGF23 GALNT3 KL PHEX RUNX2
10 mortality/aging MP:0010768 10 SLC34A1 VDR CASR FGF23 GCM2 GNAS
11 limbs/digits/tail MP:0005371 9.92 FGF23 GALNT3 GNAS KL PHEX PTH
12 integument MP:0010771 9.91 CASR FGF23 GALNT3 GNAS KL RUNX2
13 muscle MP:0005369 9.76 SLC34A1 VDR CASR GALNT3 GNAS KL
14 renal/urinary system MP:0005367 9.65 CASR FGF23 GALNT3 GCM2 GNAS KL
15 skeleton MP:0005390 9.44 PTH RUNX2 SLC34A1 STX16 VDR CASR

Drugs & Therapeutics for Hyperphosphatemia

Drugs for Hyperphosphatemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 87)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 471-34-1
2
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
3
Calcium acetate Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 62-54-4
4
Sevelamer Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52757-95-6
5
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
6
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
8
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 1 59-67-6 938
9
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 1 98-92-0 936
10
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 77-92-9 311
11
Alfacalcidol Approved, Nutraceutical Phase 4,Not Applicable 41294-56-8 5282181
12
Calcitriol Approved, Nutraceutical Phase 4,Phase 2,Not Applicable 32222-06-3 134070 5280453
13
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2,Not Applicable 50-14-6 5280793
14
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1406-16-2
15
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 2 67-97-0 6221 5280795
16
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
17 Antacids Phase 4,Phase 3,Phase 2,Not Applicable
18 Antimetabolites Phase 4,Phase 2,Phase 1
19 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Not Applicable
20 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Hypolipidemic Agents Phase 4,Phase 2,Phase 1
24 Lipid Regulating Agents Phase 4,Phase 2,Phase 1
25 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Nicotinic Acids Phase 4,Phase 2,Phase 1
27 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Vasodilator Agents Phase 4,Phase 2,Phase 1
29 Vitamin B Complex Phase 4,Phase 2,Phase 1
30 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1
32 Chelating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Ferric Compounds Phase 4,Phase 3,Phase 2
34 Hematinics Phase 4,Phase 3,Phase 2
35 Hormones Phase 4,Phase 3
36 Hydroxycholecalciferols Phase 4,Not Applicable
37 Vasoconstrictor Agents Phase 4,Phase 2,Not Applicable
38 Ergocalciferols Phase 4,Phase 2,Not Applicable
39 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Not Applicable
40 Calcimimetic Agents Phase 4
41 Cinacalcet Hydrochloride Phase 4
42 Hormone Antagonists Phase 4,Phase 3
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
44 Anticholesteremic Agents Phase 4
45 Atorvastatin Calcium Phase 4 134523-03-8
46 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
47 Liver Extracts Phase 4
48 Protective Agents Phase 4,Phase 2
49 Antioxidants Phase 4
50 Calcifediol Phase 4 19356-17-3

Interventional clinical trials:

(show top 50) (show all 176)
# Name Status NCT ID Phase Drugs
1 Nicotinic Acid in Hemodialysis Patients With Hyperphosphatemia Unknown status NCT02836184 Phase 4 Nicotinic Acids;Calcium Carbonate
2 A Study of Ferric Citrate to Improve Inflammation and Lipid Levels Unknown status NCT02661295 Phase 4 Ferric Citrate
3 Alendronate for Vascular Calcification in Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
4 More Frequent Dialysis (>3 Treatments Per Week) Unknown status NCT00575497 Phase 4
5 Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients Completed NCT01755078 Phase 4 Sevelamer HCl;Calcium-based phosphate binder
6 Phosphate Kinetic Modeling 2 Completed NCT01252771 Phase 4
7 Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease Completed NCT00160121 Phase 4 Lanthanum carbonate
8 Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism Completed NCT01115543 Phase 4 alfacalcidol and calcitriol
9 Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Completed NCT00891813 Phase 4 Zemplar (paricalcitol)
10 Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism Completed NCT00307840 Phase 4 paricalcitol
11 Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients Completed NCT01427907 Phase 4 Calcium acetate oral solution (COS);Sevelamer carbonate
12 Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Completed NCT00537979 Phase 4 Paricalcitol injection;Paricalcitol capsules
13 20070360 Incident Dialysis Completed NCT00803712 Phase 4 Cinacalcet;Vitamin D
14 Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis Completed NCT00091481 Phase 4 Zemplar
15 CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
16 Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis Recruiting NCT03256838 Phase 4 Ferric Citrate
17 Phophate Lowering Trial Recruiting NCT02209636 Phase 4 Lanthanum carbonate;placebo;Ascorbic Acid;Nitroglycerin
18 TOnicity of Perioperative Maintenance SoluTions Recruiting NCT03080831 Phase 4 NaCl 0.9% in Glucose 5% + 40mmol/L Potassium;Glucion 5%
19 Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia Enrolling by invitation NCT02237534 Phase 4 Lanthanum carbonate;Calcium Carbonate
20 The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis Not yet recruiting NCT03163576 Phase 4 Niacin;Phosphate Binder
21 Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients Not yet recruiting NCT03079869 Phase 4 Ferric Citrate
22 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Not yet recruiting NCT03176849 Phase 4
23 Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5 Terminated NCT00452478 Phase 4 Lanthanum carbonate
24 Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol Terminated NCT01725113 Phase 4 Calcitriol;Paricalcitol
25 Vitamin D and Carboxy PTH Fragments in Coronary Calcification Withdrawn NCT00502268 Phase 4 Doxercalciferol administration;Doxercalciferol administered by 1-84-7-84
26 Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction Unknown status NCT01357317 Phase 3 Phosphorus binder
27 A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01833494 Phase 3 PA21
28 An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD) Completed NCT02675998 Phase 3 Tenapanor;Placebo
29 Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients Completed NCT01518387 Phase 3 Lanthanum Carbonate (BAY77-1931)
30 Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate Completed NCT01514851 Phase 3 Lanthanum carbonate (BAY77-1931);Calcium carbonate
31 A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850602 Phase 3 PA21;Sevelamer hydrochloride
32 Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00772382 Phase 3 MCI-196
33 A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia Completed NCT01852682 Phase 3 PA21
34 A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850641 Phase 3 PA21
35 Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742611 Phase 3 ASP1585
36 Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis Completed NCT00892749 Phase 3 ASP1585
37 A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742585 Phase 3 ASP1585;placebo
38 A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia Completed NCT00416520 Phase 3 MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®);Placebo;Another phosphate binder (Sevelamer)
39 A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00542815 Phase 3 MCI-196;Another Phosphate binder (Sevelamer)
40 A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis Completed NCT01017276 Phase 3 ASP1585
41 A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis Completed NCT01057407 Phase 3 ASP1585;Sevelamer hydrochloride
42 A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia Completed NCT00506441 Phase 3 MCI-196;Placebo
43 Long-term Study in Chronic Kidney Disease (Extension From Study 14817) Completed NCT01187628 Phase 3 Fosrenol (Lanthanum Carbonate, BAY77-1931)
44 A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia Completed NCT00542386 Phase 3 MCI-196;Placebo
45 Study in Chronic Kidney Disease (CKD) Not on Dialysis Completed NCT01110629 Phase 3 Fosrenol (Lanthanum Carbonate, BAY77-1931);Placebo
46 A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients Completed NCT01324128 Phase 3 PA21 (2.5 g tablet containing 500 mg iron);Sevelamer carbonate;PA21-1 (1.25 g tablet containing 250 mg iron)
47 A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients Completed NCT01464190 Phase 3 PA21 (2.5 g tablet containing 500 mg iron);Sevelamer carbonate
48 Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients Completed NCT01069692 Phase 3 SBR759A;SBR759A;SBR759A;SBR759A;SBR759A
49 A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease Completed NCT01074125 Phase 3 ferric citrate
50 Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules Completed NCT02027662 Phase 2, Phase 3 Osvaren Granules;Osvaren film-coated tablets

Search NIH Clinical Center for Hyperphosphatemia

Cochrane evidence based reviews: hyperphosphatemia

Genetic Tests for Hyperphosphatemia

Genetic tests related to Hyperphosphatemia:

# Genetic test Affiliating Genes
1 Hyperphosphatemia 29

Anatomical Context for Hyperphosphatemia

MalaCards organs/tissues related to Hyperphosphatemia:

41
Kidney, Bone, Liver, Heart, Smooth Muscle, Endothelial, Colon

Publications for Hyperphosphatemia

Articles related to Hyperphosphatemia:

(show top 50) (show all 469)
# Title Authors Year
1
Calcitriol accelerates vascular calcification irrespective of vitamin K status in a rat model of CKD with hyperphosphatemia and secondary hyperparathyroidism. ( 29903718 )
2018
2
Dietary Management ofA Hyperphosphatemia. ( 29655498 )
2018
3
Patient education for hyperphosphatemia management: Improving outcomes while decreasing costs? ( 29629272 )
2018
4
NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD. ( 29340316 )
2018
5
Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis. ( 29295646 )
2018
6
Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease. ( 29566839 )
2018
7
Phosphate stimulates myotube atrophy through autophagy activation: evidence of hyperphosphatemia contributing to skeletal muscle wasting in chronic kidney disease. ( 29486729 )
2018
8
The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. ( 29617976 )
2018
9
Current and potential treatment options for hyperphosphatemia. ( 29783873 )
2018
10
Nicotinic acid and related compounds: A meta-analysis of their use for hyperphosphatemia in dialysis patients. ( 29561409 )
2018
11
Prevention and treatment of hyperphosphatemia in chronic kidney disease. ( 29580635 )
2018
12
A Decision Support Tool for Healthcare Professionals in the Management of Hyperphosphatemia in Hemodialysis. ( 29678073 )
2018
13
Blood pressure and heart rate variability are linked with hyperphosphatemia in chronic kidney disease patients. ( 29947550 )
2018
14
Hyperphosphatemia is associated with high mortality in severe burns. ( 29315336 )
2018
15
Hyperphosphatemia induces senescence in human endothelial cells by increasing endothelin-1 production. ( 28857396 )
2017
16
Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study. ( 28550969 )
2017
17
Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease. ( 28777915 )
2017
18
Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model. ( 28078600 )
2017
19
Effect of Vitamin D Supplementation on Delayed Hyperphosphatemia in Pediatric Acute Lymphoblastic Leukemia Patients During Induction Chemotherapy. ( 28469534 )
2017
20
A Case of Hyperphosphatemia and Elevated Fibroblast Growth Factor 23: A Brief Review of Hyperphosphatemia and Fibroblast Growth Factor 23 Pathway. ( 29270533 )
2017
21
Cost-effectiveness of dedicated dietitians for hyperphosphatemia management among hemodialysis patients in Lebanon: results from the Nutrition Education for Management of Osteodystrophy trial. ( 28657451 )
2017
22
Analysis of Hypo- and Hyperphosphatemia in an Intensive Care Unit Cohort. ( 28525508 )
2017
23
Hyperphosphatemia and hs-CRP Initiate the Coronary Artery Calcification in Peritoneal Dialysis Patients. ( 28321403 )
2017
24
Educational nursing intervention to reduce the hyperphosphatemia in patients on hemodialysis. ( 28226039 )
2017
25
Diabetes Mellitus and Younger Age Are Risk Factors for Hyperphosphatemia in Peritoneal Dialysis Patients. ( 28218647 )
2017
26
Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease. ( 28533541 )
2017
27
Hyperphosphatemia in a patient with spinal cord injury who received etidronate for the treatment of heterotopic ossification. ( 28616259 )
2017
28
A Dialysis Patient With Hyperphosphatemia, Hyperkalemia, and Azotemia Without an Excessive Intake. ( 29142992 )
2017
29
Surface-Engineered Blood Adsorption Device for Hyperphosphatemia Treatment. ( 28799951 )
2017
30
Activation of the Nrf2-ARE Signaling Pathway Prevents Hyperphosphatemia-Induced Vascular Calcification by Inducing Autophagy in Renal Vascular Smooth Muscle Cells. ( 28513870 )
2017
31
Antibody-mediated inhibition of EGFR reduces phosphate excretion and induces hyperphosphatemia and mild hypomagnesemia in mice. ( 28292888 )
2017
32
Tumor lysis syndrome with massive hyperphosphatemia and hyperuricemia. ( 29225880 )
2017
33
Uremic Tumoral Calcinosis Resolved by Improvements in Hyperphosphatemia. ( 28626193 )
2017
34
Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia. ( 28182142 )
2017
35
Hyperphosphatemia, a Cause of High Anion Gap Metabolic Acidosis: Report of a Case and Review of the Literature. ( 28450695 )
2017
36
Admission hyperphosphatemia increases the risk of acute kidney injury in hospitalized patients. ( 28975589 )
2017
37
Comment on: "Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Mode". ( 28528515 )
2017
38
Transient hyperphosphatemia in a child with nephrolithiasis and severe prematurity. ( 28325562 )
2017
39
Short-Term PTH(1-34) Therapy in Children to Correct Severe Hypocalcemia and Hyperphosphatemia due to Hypoparathyroidism: Two Case Studies. ( 27957353 )
2016
40
Treating hyperphosphatemia - current and advancing drugs. ( 27643443 )
2016
41
Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients. ( 27121505 )
2016
42
Economic Evaluation of Sevelamer versus Calcium-based Binders in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China. ( 27751671 )
2016
43
The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis. ( 27651467 )
2016
44
Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials. ( 26668024 )
2016
45
Transient hyperphosphatemia: a benign laboratory disorder in a boy with Gitelman syndrome. ( 27737396 )
2016
46
Spurious Hyperphosphatemia: A Diagnostic and Therapeutic Challenge. ( 26706383 )
2016
47
Ornithine is a key mediator in hyperphosphatemia-mediated human umbilical vein endothelial cell apoptosis: Insights gained from metabolomics. ( 26773858 )
2016
48
Chronic Hyperphosphatemia and Vascular Calcification Are Reduced by Stable Delivery of Soluble Klotho. ( 27837149 )
2016
49
Phenotypic and Genotypic Characterization and Treatment of a Cohort with Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome. ( 27164190 )
2016
50
Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. ( 27933339 )
2016

Variations for Hyperphosphatemia

Expression for Hyperphosphatemia

Search GEO for disease gene expression data for Hyperphosphatemia.

Pathways for Hyperphosphatemia

GO Terms for Hyperphosphatemia

Cellular components related to Hyperphosphatemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.26 CASR GNAS KL SLC34A1
2 perinuclear region of cytoplasm GO:0048471 9.02 GALNT3 GNAS PHEX SLC34A1 STX16

Biological processes related to Hyperphosphatemia according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 cellular calcium ion homeostasis GO:0006874 9.71 CASR GCM2 PTH VDR
2 fibroblast growth factor receptor signaling pathway GO:0008543 9.7 FGF23 GALNT3 KL
3 ossification GO:0001503 9.67 CASR MGP RUNX2 SLC34A1
4 positive regulation of bone mineralization GO:0030501 9.62 KL PTH
5 embryonic cranial skeleton morphogenesis GO:0048701 9.62 GNAS RUNX2
6 response to cadmium ion GO:0046686 9.61 PTH SLC34A1
7 endochondral ossification GO:0001958 9.61 GNAS RUNX2
8 response to lead ion GO:0010288 9.6 PTH SLC34A1
9 regulation of bone mineralization GO:0030500 9.59 FGF23 MGP
10 response to vitamin D GO:0033280 9.58 PHEX PTH
11 obsolete positive regulation of cAMP biosynthetic process GO:0030819 9.58 GNAS PTH
12 vitamin D metabolic process GO:0042359 9.57 FGF23 VDR
13 energy reserve metabolic process GO:0006112 9.56 GNAS KL
14 response to growth hormone GO:0060416 9.55 PHEX SLC34A1
15 response to magnesium ion GO:0032026 9.54 FGF23 SLC34A1
16 response to fibroblast growth factor GO:0071774 9.51 CASR PTH
17 cellular response to vitamin D GO:0071305 9.5 CASR FGF23 PHEX
18 positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway GO:0090080 9.49 FGF23 KL
19 phosphate ion homeostasis GO:0055062 9.48 FGF23 SLC34A1
20 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.46 FGF23 VDR
21 response to sodium phosphate GO:1904383 9.43 FGF23 PHEX
22 cellular response to parathyroid hormone stimulus GO:0071374 9.43 FGF23 PHEX SLC34A1
23 skeletal system development GO:0001501 9.35 GNAS PHEX PTH RUNX2 VDR
24 cellular phosphate ion homeostasis GO:0030643 9.33 FGF23 GCM2 SLC34A1
25 response to parathyroid hormone GO:0071107 8.8 GNAS PTH SLC34A1

Molecular functions related to Hyperphosphatemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibroblast growth factor receptor binding GO:0005104 8.96 FGF23 KL
2 vitamin D binding GO:0005499 8.62 KL VDR

Sources for Hyperphosphatemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....